Osteosarcoma and other tumors of bone

Current Opinion in Oncology

Volumn 8, Issue 4, 1996, Pages 299-304

  Mertens, Wilson C ^a   Bramwell, Vivien H C ^b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE;

AMPUTATION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL ONCOGENE; DIAGNOSTIC IMAGING; HUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0029762259     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199607000-00006     Document Type: Review

References (51)

1. Doll R: The epidemiology of childhood leukemia. J R Stat Soc 1992. 152:341-351.
2. Gurney JG, Severson RK, Davis S, Robison LL: Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995, 75:2186-2195. One-year incidence rates for childhood cancer reveal considerable variation for the incidence of solid tumors in childhood.
3. Mertens F, Mandahl N, Orndal C, Baldetrop B, Bauer HCF, Rydholm A, Wiebe T, Willen H, Akerman M, Heim S, Mitelman F: Cytogenetic findings in 33 osteosarcomas. Int J Cancer 1993, 55:44-50.
4. Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, Böhling T, Karaharju E, Hyytinen E, Knuutila S, Kallioniemi O-P; Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 1995, 55:1334-1338. High-level amplification of small chromosomal regions were seen at 12q12-q13, which contains the MDM2 locus, as well as at several previously unreported loci. Gains at 8q and Xp were most common. Common sites of loss were 2q, Gq, 8p, and 10p.
5. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O: MDM2 amplification and transfer levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 1994, 86:1297-1302.
6. Maelandsmo GM, Berner J-M, Flørenes VA, Forus A, Hovig E, Fodstad Ø, Myklebost O: Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas: relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995, 72:393-398. The authors suggest that aberrations in these genes, which participate in the regulation of the cell cycle, may be important in the development of sarcomas, but the variable presence of homozygous CDKN2 deletions may reflect differing importance of this mechanism in different sarcomas.
7. Ron IG, Amir G, Inbar MJ, Chaitchik S: Clear cell chondrosarcoma of rib following repetitive low-impact trauma. Am J Clin Oncol 1995, 18:87-89. A case of a sarcoma of rib arising in an area subjected to trauma for 24 years, raising the possibility that increased new bone formation may be related to the genesis of this tumor.
8. Ferracini R, di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini PL, Cremona O, Campanacci M, Comoglio PM: The met/HGF receptor is over expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit Oncogene 1995, 10:739-749. The c-MET oncogene encodes the receptor for hepatocyte growth factor, a cytokine that stimulates the invasive growth of normal and cancerous cells. Activation of the receptor by paracrine or autocrine mechanisms might play a role in the aggressive behavior of osteosarcomas.
9. Noteborn MHM, Todd D, Verschueren CAJ, de Gauw HWFM, Curran WL, Veldkamp S, Douglas AJ, McNulty MS, van der Eb AJ, Koch G: A single chicken anemia virus protein induces apoptosis. J Virol 1994, 68:346-351.
10. Zhuang S-M, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb AJ, Noteborn MHM: Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res 1995, 55:486-489. Apoptin induces apoptosis independently of p53 protein status, suggesting a future therapy for malignancies that do not contain functional (wild type) p53 protein.
11. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993, 74:957-967.
12. Warters RL: Radiation-induced apoptosis in a murine T-cell hybridoma. Cancer Res 1992, 52:883-890.
13. Anderson PM, Meyers DE, Hasz DE, Covalcuic K, Saltzman D, Khanna C, Uckun FM: In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein. Cancer Res 1995, 55:1321-1327. A conjugated cytotoxic monoclonal antibody, which reacts with an antigen on human and canine osteosarcoma cells, induces a dose-dependent reduction in pulmonary metastases 3 to 5 days after tumor inoculation in a murine model. This antibody may represent a promising new therapy for evaluation in future clinical trials.
14. Schwarte HS, Juliao SF, Sciadini MF, Miller LK, Butler MG: Telomerase activity and oncogenesis in giant cell tumor of bone. Cancer 1995, 75:1094-1099. Telomerase or telomerase-like activity was not found in fibroblasts, but was detected to a variable degree in giant cell tumor cells. The human cell line HeLa, which was used as a positive control, demonstrated more activity than did giant cell tumor cells. Telomere reduction was found in both HeLa and giant cell tumor cells, but not in fibroblasts.
15. Zheng MH, Fan Y, Panicker A, Smith A, Robertson T, Wysocki S, Robbins P, Papadimitriou JM, Wood DJ: Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. Am J Pathol 1995, 147:1559-1566. The urokinase-type plasminogen activation system has been implicated in the ability of some malignancies to invade and metastasize. Evidence for abnormalities in this system in giant cell tumor of bone is presented.
16. Bruland ØS, Fodstad Ø, Aas M, Solheim ØP, Høie J, Skretting A, Winderen M, Michaelsen T, Pihl A: Immunoscintigraphy of bone sarcomas: results in 5 patients. Eur J Cancer 1994, 30A: 1484-1489.
17. Bruland ØS, Fodstad Ø, Stenwig AE, Pihl A: Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. Cancer Res 1988, 48:5302-5309.
18. Bruland ØS, Fodstad Ø, Funderud S, Pihl A: New monoclonal antibodies specific for human sarcomas, Int J Cancer 1986, 38:27-31.
19. Lang P, Grampp S, Vahlensieck M, Johnson JO, Honda G, Rosenau W, Matthay KK, Peterfy C, Higgins CB, Genant HK, Gooding CA: Primary bone tumors: value of MR angiography for preoperative planning and monitoring response to chemotherapy. AJR Am J Roentgenol 1995, 165:135-142. Magnetic resonance angiography provided good visualization of peripheral vascular branches and tumor neovascularity in primary bone tumors, and it demonstrated encroachment onto and encasement of major vessels. Magnetic resonance angiography was also useful to assess response to chemotherapy, with good correlation of induced changes in tumor neovascularity with chemotherapy-induced necrosis demonstrated.
20. Swan JS, Grist TM, Sproat IA, Heiner JP, Wiersma SR, Heisey DM: Musculoskeletal neoplasms: preoperative evaluation with MR angiography. Radiology 1995, 194:519-524. Magnetic resonance angiography was able to identify major vessels and feeders, but some feeders were hard to distinguish due to a lack of associated tumor blush.
21. van der Woude H-J, Bloem JL, van Oostayen JA, Nooy MA, Taminiau AHM, Hermans J, Reynierse M, Hogendoorn PCW: Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response. AJR Am J Roentgenol 1995, 165:125-133. An increase in the resistive index of the feeding arteries was associated with a good histologic response to chemotherapy in Ewing sarcoma and osteosarcoma.
22. van der Woude H-J, Bloom JL, Schipper J, Hermans J, van Eck-Smit BLF, van Oostayen J, Nooy MA, Taminiau AHM, Olscher HC, Hogendoorn PCW: Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrastenhanced MR imaging and 3-phase bone scintigraphy. Radiology 1994, 191:421-431
23. Saeter G, Høie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim ØP: Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer 1995, 75:1084-1093. Complete metastasectomy is important for long-term survival of patients with metastatic osteosarcoma. Repeated pulmonary resections were necessary in almost one half of the patients.
24. Temeck BK, Wexler LH, Steinberg SM, McClure LL, Horowitz M, Pass HI: Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg 1995, 59:1385-1390. Unfavorable factors for survival by Cox proportional hazards model were incomplete resection (P < 0.0001), nonosteosarcoma histology (P = 0.0054), and three or more tumor nodules (P = 0.021). The authors concluded that a complete resection is vital.
25. Pacquement H, Blanchard C, Kalifa C, Fagnou C, Demaille MC, Brunat Mentigny M, Sariban E, Perel Y, Zucker JM: Metastatic osteogenic sarcoma at diagnosis: study of 73 cases treated by the French Society of Pediatric Oncology (SFOP) [abstract]. Proc ASCO 1995, 14:456. Patients with bone metastases had a very poor prognosis; the improved prognosis of patients with isolated lung metastases was related to a good histologic response to chemotherapy.
26. Scotlandi K, Serra M, Manara MC, Maurici D, Benini S, Nini G, Campanacci M, Baldini N: Clinical relevance of Ki-67 expression in bone tumors. Cancer 1995, 75:806-814. The authors speculated that given the results of this study (which included 30 patients treated with limb-salvage surgery and the same chemotherapy regimen), Ki-67 labeling index may become more useful in determining prognosis than histologic response to chemotherapy.
27. Schajowicz F, Sissons HA, Sobin LH: The World Health Organization's Histologic Classification of Bone Tumors: a commentary on the second edition. Cancer 1995, 75:1204-1214. The second edition is described and contrasted with the first, highlighting changes and additions to the classification.
28. Simms WW, Ordonez NG, Johnston D, Ayala AG, Czerniak B: p53 Expression in dedifferentiated chondrosarcoma. Cancer 1995, 76:223-227. The percentage of p53-positive cells paralleled the proliferating cell fraction of the various histologic components of this tumor, and was consistently present in high-grade noncartilaginous component of the tumor.
29. Bertoni F, Unni KK, Beabout JW, Sim FH: Parosteal osteoma of bones other than of the skull and face. Cancer 1995, 75:2466-2473. This tumor must be distinguished from parosteal osteosarcoma, and the authors suggest that if radiographs fail to detect areas of radiolucency and histologic sections do not demonstrate spindle cells, a diagnosis of parosteal osteoma is appropriate.
30. Hazelbag HM, Fleuren GJ, Cornelisse CJ, van den Broek LJCM, Taminiau AHM, Hogendoorn PCW: DNA aberrations in the epithelial cell component of adamantinoma of long bones. Am J Pathol 1995, 147:1770-1779. Forty percent of tumors evaluated were aneuploid and 48% stained strongly for p53 protein, with staining restricted to the epithelial cells. In sections taken from the pulmonary metastases of seven patients, only the epithelial component was represented, with no evidence in these secondary tumors of the osteofibrous component demonstrated in the primary lesion.
31. Windhager R, Millesi H, Kotz R: Resection-replantation for primary malignant tumours of the arm: an alternative to fore-quarter amputation. J Bone Joint Surg [Br] 1995, 77-B:176-184. Despite often limited hand function, patients appeared to be satisfied with the outcome, which avoided amputation and resulted in no local recurrences.
32. Said GZ, El-Sherif EK: Resection-shortening-distraction for malignant bone tumors: a report of two cases. J Bone Joint Surg [Br] 1995, 77-B:185-188. A technique that avoided both bone grafting and multiple surgical procedures, as well as amputation.
33. Hurson BJ: Limb-sparing surgery for patients with sarcomas. J Bone Joint Surg [Br] 1995, 77-B:173-174.
34. Capanna R, Manfrini M, Briccoli A, Gherlinzoni F, Lauri G, Caldora P: Latissimus dorsi pedicled flap applications in shoulder and chest wall reconstructions after extracompartimental sarcoma resections. Tumori 1995, 81:56-62. Latissimus dorsi pedicled flap reconstructions are a reliable technique to reconstruct large chest wall and shoulder soft tissue defects.
35. Dreinhofer KE, Rydholm A, Bauer HCF, Kreicbergs A: Giant-cell tumours with fracture at diagnosis: curettage and acrylic cementing in ten cases. J Bone Joint Surg [Br] 1995, 77-B:189-193. Four patients suffered a local recurrence, of whom three were "cured" with repeat curettage and cementing.
36. Tai PTH, Craighead P, Bagdon F: Optimization of radiotherapy for patients with cranial chordoma. Cancer 1995, 75:749-756. Combined surgery and radiotherapy is preferred to either modality alone in the treatment of these neoplasms. The authors speculated that newer methods such as proton beams and radiosurgery will require further study.
37. Goorin A, Baker A, Gieser P, Ayala A, Gebhardt M, Harris M, Weiner M, Cantor A, Grier H, Vietti T, Link M: No evidence for improved event free survival [EFS] with presurgical chemotherapy [PRE] for non-metastatic extremity osteogenic sarcoma [OGS]: preliminary results of randomized Pediatric Oncology Group [POG] trial 8651 [abstract]. Proc ASCO 1995, 14:444. No difference in event-free survival was seen between patient groups randomized to neoadjuvant and adjuvant chemotherapy or to adjuvant chemotherapy only.
38. Meyers P, Casper E, Huvos A, Lane J, Healey J, Marcove R: A prospective randomized trial of intensive pre-operative (PRE-OP) chemotherapy (CHEMO) versus CHEMO guided by histologic response (HR) to PRE-OP CHEMO [abstract]. Proc ASCO 1993, 12:412.
39. Bramwell VHC: The role of chemotherapy in osteogenic sarcoma. Crit Rev Oncol Hematol 1995, 20:61-85.
40. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois J-C: Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy in osteosarcoma. Anticancer Res 1995, 15:489-494. Employing pharmacokinetic monitoring, the dose of methotrexate was optimized, resulting in an apparent improvement in histologic response.
41. Goorin A, Strother D, Poplack D, Letvak LA, George M, Link M: Safety and efficacy of I-leucovorin rescue following high-dose methotrexate for osteosarcoma. Med Pediatr Oncol 1995, 24:362-367. The I-leucovorin isomer was effective in rescuing patients from methotrexate toxicity.
42. Epelman S, Seibel N, Melaragno R, Silva A, Penna W, Goncalves J, Miser J, Camargo AC: Treatment of newly diagnosed high grade osteosarcoma (OS) with ifosfamide (IFOS), adriamycin (ADR) and cisplatin (CDP) without high dose methotrexate [abstract]. Proc ASCO 1995, 14:439. Sixty patients were treated and with a median follow-up of 1 year, the actuarial overall survival rate was 92% and the progression-free survival rate 93%.
43. Benjamin RS, Patel SR, Armen T, Carrasco CH, Raymond AK, Ayala AG, Chawla SP, Yasko AW, Murray JA: The value of ifosfamide in postoperative neoadjuvant chemotherapy of osteosarcoma [abstract]. Proc ASCO 1995, 14:516. By comparison to historic data, the authors believe that the addition of ifosfamide improves the results (as measured by continuous disease free survival) of neoadjuvant chemotherapy in those patients who demonstrated suboptimal histologic response.
44. Meyer WH, Pratt CB, Harper J, Fletcher B, Kaste S, Luo X, Mahmoud H, Parham D, Rao BN: Ifosfamide (IFOS) and carboplatin (CARBO) window therapy in previously untreated osteosarcoma (OS) [abstract]. Proc ASCO 1995, 14:442. The combination yielded superior results when retrospectively compared with ifosfamide alone.
45. Harris M, Gieser P, Link M, Goorin A, Ayala A, Shochat S, Ferguson W, Holbrook T Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group study [abstract]. Proc ASCO 1995, 14.445. Two courses of ifosfamide, followed by surgery and further chemotherapy with high-dose methotrexate, ifosfamide, doxorubicin and cisplatin, were administered to patients with metastatic osteosarcoma at diagnosis. After the initial ifosfamide therapy, a response rate of 33% was seen.
46. Kleinerman E, Gang J, Raymond A, Corpron C, Papadopoulos N, Patel S, Benjamin R, Jaffe N: Phase II study of recombinant IL-1α plus etoposide in relapsed osteosarcoma (OS) [abstract]. Proc ASCO 1995, 14:518. Etoposide and interleukin-1α may be synergistic in patients with osteosarcoma.
47. Jia SF, Zwelling LA, Kleinerman ES: Antitumor effect of IL-1α and VP-16, ADR, mAMSA, VBL, TPT, cDDP against osteosarcoma cells [abstract]. Proc AACR 1995, 36:480.
48. Kleinerman ES, Gang JB, Johnston DA, Benjamin RS, Jaffe N: Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995, 18:93-99. Patients who received 24 weeks of therapy appeared to have a significant prolongation in time to relapse compared with historic control subjects, whereas those who received 12 weeks of therapy did not.
49. Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, Obradovich J, Fidel J, Rosenberg M: Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995, 1:1595-1601. No survival advantage was seen with the concurrent administration of cisplatin and L-MTP-PE.
50. Samuels BL, Simon MA: Successful aggressive induction chemotherapy for radiation-induced (RI) bone sarcoma [abstract]. Proc ASCO 1995, 14:520 Four patients with radiation-associated bone sarcomas were treated with intraarterial cisplatin and intravenous doxorubicin prior to definitive local therapy. Two patients are long-term survivors, suggesting that aggressive therapy is warranted despite the poor outcome that has been attributed to these malignancies.
51. Patel SR, Benjamin RS: Primary extra skeletal osteosarcoma: experience with chemotherapy. J Natl Cancer Inst 1995, 87:1331-1333. Cisplatin-based chemotherapy achieved only a modest benefit in these patients.